SCHEMBL2205953

SCHEMBL2205953

O=C1N[C@H](CO)CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL962003 1.00
SCHEMBL1775806 1.00
SCHEMBL19128284 0.83
SCHEMBL9833318 0.83
SCHEMBL15879468 0.79 HLCS (0.32)
SCHEMBL15879470 0.79 HLCS (0.32)
SCHEMBL14638692 0.79
SCHEMBL17365148 0.78
SCHEMBL23535429 0.77
SCHEMBL18360767 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117402085-A Novel method for synthesizing D-N-BOC-biphenylpropylamine 迪嘉药业集团股份有限公司 2024-01-16 CN claimed
US-20020052511-A1 Process for the preparation of matrix metalloproteinase inhibitors BAILEY ANNE E (US) 2002-05-02 US claimed
US-20020019539-A1 Process for the preparation of matrix metalloproteinase inhibitors ABBOTT LABORATORIES 2002-02-14 US claimed
WO-2024226892-A1 HYDRAZONE 3H-IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND USES THEREOF Verge Analytics, Inc. (US) 2024-10-31 WO disclosed
CN-117402085-A Novel method for synthesizing D-N-BOC-biphenylpropylamine 迪嘉药业集团股份有限公司 2024-01-16 CN disclosed
EP-3559007-B1 SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY DAIICHI SANKYO CO LTD (JP) 2023-08-16 EP disclosed
US-11396505-B2 Inhibitors of CaMKK2 and uses of same NEW YORK UNIVERSITY (US) 2022-07-26 US disclosed
CN-110167946-B Sulfonamide compounds having TNAP inhibitory activity 第一三共株式会社 2022-04-08 CN disclosed
US-20220098176-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2022-03-31 US disclosed
US-11046710-B2 Sulfonamide compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-29 US disclosed
US-11014939-B2 2021-05-25 US disclosed
WO-2014106660-A1 NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS PIERRE FABRE MEDICAMENT (FR) 2014-07-10 WO disclosed
US-8501794-B2 Compounds as cannabinoid receptor ligands ABBVIE INC. (US) 2013-08-06 US disclosed
CN-102272111-A 1,2 -thiazol yl derivatives as cannabinoid receptor ligands 2011-12-07 CN disclosed
EP-2344463-A2 1,2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS Abbott Laboratories (US) 2011-07-20 EP disclosed
US-20100234345-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-09-16 US disclosed
WO-2010054024-A2 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-05-14 WO disclosed
US-6441189-B1 WHICH REDUCES RACEMIZATION; (4R)-4-(HYDROXYMETHYL)-1,3-OXAZOLIDIN-2-ONE BY REDUCTION AND BASIFICATION OF THE CORRESPONDING 4-PROTECTED CARBOXY ESTER ABBOTT LABORATORIES 2002-08-27 US disclosed
US-20020052511-A1 Process for the preparation of matrix metalloproteinase inhibitors BAILEY ANNE E (US) 2002-05-02 US disclosed
US-20020019539-A1 Process for the preparation of matrix metalloproteinase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed